ACRSAclaris Therapeutics, Inc.

$435M

Q4 2021 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$2M-5.0% YoY

Gross Profit

$352,00023.5% margin

Operating Income

-$23M-1525.2% margin

Net Income

-$23M-1519.3% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

-9.5%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$251M

Total Liabilities

$54M

Stockholders' Equity

$197M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$2M	-5.0%
Gross Profit	$352,000	$294,000	+19.7%
Operating Income	-$23M	-$14M	-68.8%
Net Income	-$23M	-$13M	-73.1%

Revenue Segments

Contract research

$1M85%

Other revenue

$227,00015%

ACRS Q4 2021 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena